Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159406 | 0.87 | KDM6B (0.40) | KDM6BKDM4CCISD1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3855171 | 0.80 | KDM6B (0.43) | KDM6BKDM4CCISD1JAK2KDM4E | |
| Hydrochloric Acid SCHEMBL4365233 | 0.73 | NNMT (0.32) | JAK2HSD17B10JAK1JAK3 | |
| SCHEMBL3860110 | 0.73 | BACE1 (0.45) | HCAR3EPHX2 | |
| SCHEMBL5153914 | 0.67 | KDM6B (0.41) | KDM6BKDM4CCISD1KDM4EALDH1A1 | |
| SCHEMBL5158280 | 0.67 | HCAR3 (0.46) | KDM4EALDH1A1HPGDHSD17B10HCAR3 | |
| SCHEMBL5158867 | 0.65 | KDM4C (0.59) | KDM6BKDM4CCISD1KDM4EHCAR3 | |
| SCHEMBL5159403 | 0.65 | BACE1 (0.42) | KDM4EALDH1A1HSD17B10HCAR3 | |
| SCHEMBL14577687 | 0.64 | TSHR (0.53) | KDM6BKDM4CKDM4EALDH1A1HPGD | |
| SCHEMBL2429407 | 0.64 | CISD1 (0.53) | KDM6BKDM4CCISD1HSD17B10HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585885-B2 | Pyrrolidine derivatives useful as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | ELI LILLY AND COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | BACE1, BACE2, PSEN1 | KDM6B 1726/4885KDM4C 2623/4885CISD1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.